MCAS That Does Not Respond to Standard Stabilizers

What the standard model gets wrong

The standard model treats MCAS as a primary mast cell disease. The cell is overactive, and the treatment is to dampen it. H1 antagonists, H2 antagonists, cromolyn, ketotifen, leukotriene blockers, sometimes omalizumab. The strategy works in many patients and produces durable improvement. In a subset, it does not. That subset is the population this page is about.

When stabilization is layered up to maximum dose and the patient is still flaring, the conventional move is to add another stabilizer. This is a coherent move only if the problem is intrinsic mast cell excitability. If the problem is what is activating the cell, more stabilization is rate-limited by definition.

Refractory MCAS in the post-viral, post-antibiotic, post-dysbiotic population is largely driven by a stimulus the cell cannot avoid because the stimulus is internal. Treating the receptor while the stimulus continues is a partial strategy.

What the Host Capacity Model says about MCAS

Mast cells exist to detect threat. They are designed to fire on antigenic load, on endotoxin, on tissue damage. In a healthy host, these stimuli are intermittent, contained, and resolved. Mast cells fire and stand down. The system works.

In a host with a leaky barrier, sustained dysbiosis, and chronic immune activation, the stimulus does not stop. Bacterial LPS translocates across a compromised epithelium. Dysbiotic metabolites — including hydrogen sulfide, propionate excess, certain bile acid derivatives — directly signal mast cells. Post-viral antigenic persistence, where it exists, keeps the alarm wired. The cell is firing because the system is genuinely under threat. The threat is just persistent and internal.

Layered on top of this is a bioenergetic problem. Sustained immune activation upregulates CD38, which consumes NAD+. NAD+ depletion impairs mitochondrial function in every tissue, including mast cells themselves. A NAD+-depleted mast cell is both more excitable and worse at clearing the mediators it releases. This is a doubly bad state, and it is self-reinforcing — each flare drives more CD38, more NAD+ loss, more excitability.

The CD38–NAD+–SIRT3 cascade is one of the central mechanistic loops in refractory MCAS. Breaking it requires intervening at multiple points: reducing the antigenic load that drives CD38, supporting NAD+ pool restoration, and protecting mitochondrial Complex IV while the system rebalances.

Treatment that addresses the upstream load — barrier restoration, dysbiosis treatment, post-viral mitochondrial recovery — reduces the activation pressure on the mast cell. Stabilizers continue to provide symptom protection during the months-long window of recovery. The end state is a mast cell that fires appropriately because it is no longer being chronically provoked.

Patterns I look for in cases like this

• Maximally stacked antihistamines with persistent breakthrough flares.
• Tryptase that is normal or only mildly elevated despite severe clinical picture.
• Onset or amplification after a confirmed viral infection.
• Concurrent SIBO, dysbiosis, or post-antibiotic GI changes.
• Flares that track with meals, with bowel movements, or with measurable endotoxin events.
• Reactivity that has broadened over time rather than stabilized on treatment.
• Post-exertional symptom amplification suggesting mitochondrial under-resourcing.
• Connective tissue features (hypermobility, dysautonomia) suggesting hEDS-POTS-MCAS overlap.
• Disproportionate response to small additions of fermentable carbohydrate.
• A history of incremental stabilizer escalation with diminishing returns.

Tests I usually want to see

• Tryptase, chromogranin A, 24-hour urine N-methylhistamine and prostaglandin metabolites.
• Intracellular NAD+ panel — depletion is common, often below 350 μM.
• Barrier markers — zonulin, LPS, LBP, calprotectin, anti-LPS IgG.
• Shotgun metagenomics — sulfur-reducer load, butyrate producer status.
• hs-CRP, IL-6, TNF-α, ferritin — chronic immune activation panel.
• Stool short-chain fatty acid panel.
• Bile acid panel where biliary mast cell contribution is suspected.
• SIBO breath test where small bowel overgrowth is part of the picture.

Leverage points

The highest-leverage intervention is reducing the upstream antigenic and metabolic load that activates the mast cell. Barrier restoration, dysbiosis treatment where present, and attention to specific dysbiotic metabolites (sulfide-reducer dominance, propionate excess) usually deliver more clinical change than another stabilizer.

NAD+ restoration is the second leverage point. CD38 is consuming NAD+ as long as activation continues. Restoring the pool gives mitochondrial function room to recover and reduces mast cell intrinsic excitability. Dose and sustained duration matter — short courses are insufficient.

The third leverage point is keeping stabilization in place during the recovery window. Withdrawing stabilizers while the upstream lesion is being addressed exposes the patient to flares that themselves slow recovery. De-escalation comes after improvement, not before.

Where post-viral antigenic persistence is suspected, that is an additional layer. It does not change the mast cell strategy, but it shifts the timeline and frequently requires additional support beyond what this page covers.

Where this account may be wrong

Classic mastocytosis with established mast cell burden and clonal markers is a different disease and not what this account is about. Idiopathic anaphylaxis with no identifiable trigger may or may not fit the upstream-load model. The framework's strongest claim is for refractory MCAS in the post-viral, post-antibiotic, post-dysbiotic population — the group that responds inconsistently to layered stabilization. For that group the candidate upstream mechanism is well-supported. For other MCAS populations the account is partial.

Frequently asked questions

Related reading

• MCAS treatment failure FAQ
• The Host Capacity Model
• MCAS histamine patterns
• MCAS stratification guide
• Mitochondrial dysfunction
• hEDS, POTS, and MCAS overlap